Alfresa withdraws from AnGes dermatitis alliance
This article was originally published in Scrip
Alfresa Pharma has decided to withdraw from a Japanese co-development agreement for a novel nucleic acid decoy therapy for atopic dermatitis. The company, part of the Alfresa pharmaceutical wholesaling group, had been developing the nuclear factor kappa-B decoy oligodeoxynucleotide product for this use with originator AnGes MG. Mixed Phase II data which showed benefits for certain topical doses were reported earlier this year (Scrip Online, February 20th, 2008). AnGes stressed that it was pressing ahead with plans for a Phase III trial and said that it would seek a new development partner.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.